Telix Pharmaceuticals Limited is a clinical-stage biotechnology company dedicated to development and commercialisation of several advanced “theranostic” (therapeutic + diagnostic) oncology products. Our pipeline seeks to address major clinical unmet need in the management of prostate, renal (kidney) and glioblastoma (brain) cancer.

Our products are radiopharmaceuticals, which intrinsically enable superior diagnosis (imaging) and therapy of cancer. We offer better-informed treatment decisions and truly personalised therapy.

Telix’s product development strategy is to closely integrate and add value to standard care, reflective of the modern team-based approach to managing cancer in the clinical setting. Our ultimate mission is to help patients with cancer live longer with better quality lives.

Latest News


Telix Pharmaceuticals and Abzena Sign Licence Agreement for Abzena’s Prostate-Specific Membrane Antigen Antibodies

Melbourne, Australia and Cambridge, UK, July. 18, 2017 – Telix Pharmaceuticals Limited (“Telix”) is pleased...Read More
July 19, 2017

Telix Pharmaceuticals Acquires Glioblastoma Program from Therapeia

Melbourne, Australia and Dresden, Germany, Jan. 18, 2017 – Telix Pharmaceuticals Limited (“Telix”) is pleased...Read More
January 18, 2017


Nice write up in @FierceBiotech by @NickPaulTaylor. The PSMA radiopharma space is a big prize - 177Lu and beyond.


Load More...